Abstract
Anthrax caused by Bacillus anthracis is a fatal zoonotic disease with a high lethality and poor prognosis. Inhalational anthrax is the most severe of the three forms of anthrax. The currently licensed commercial human anthrax vaccines require a complex immunization procedure for efficacy and have side effects that limit its use in emergent situations. Thus, development of a better anthrax vaccine is necessary. In this study, we evaluate the potency and efficacy of aerosolized intratracheal (i.t.) inoculation with recombinant protective antigen (rPA) subunit vaccines against aerosolized B. anthracis Pasteur II spores (an attenuated strain) challenge in a B10.D2-Hc0 mouse (deficient in complement component C5) model. Immunization of rPA in liquid, powder or powder reconstituted formulations via i.t. route conferred 100% protection against a 20× LD50 aerosolized Pasteur II spore challenge in mice, compared with only 50% of subcutaneous (s.c.) injection with liquid rPA. Consistently, i.t. inoculation of rPA vaccines induced a higher lethal toxin (LeTx) neutralizing antibody titer, a stronger lung mucosal immune response and a greater cellular immune response than s.c. injection. Our results demonstrate that immunization with rPA dry powder vaccine via i.t. route may provide a stable and effective strategy to improve currently available anthrax vaccines and B10.D2-Hc0 mice challenged with B. anthracis attenuated strains might be an alternative model for anthrax vaccine candidate screening.
Highlights
Bacillus anthracis, a gram-positive, non-motile, facultative aerobic bacteria, is the causative agent of anthrax [1]
Both reconstituted powder and liquid formulations reacted with mouse polyclonal antibodies to recombinant protective antigen (rPA), and titers did not differ significantly (Figures 2A, B), demonstrating that the immunogenicity of rPA was not affected by the SFD process
Moisture content of the rPA powder was 0.663% w/w, as determined by thermogravimetric analysis (TGA) (Figure 2F). These results indicated that the rPA vaccine powder prepared was suitable for aerosol inhalation
Summary
A gram-positive, non-motile, facultative aerobic bacteria, is the causative agent of anthrax [1]. It is of great concern as a biological weapon and categorized by the Centers for Disease Control (CDC) as a category A biological threat agent [2]. Anthrax is a fatal zoonotic disease primarily observed in ungulates and humans [3]. Depending on the route of exposure, there are three forms of anthrax: cutaneous, gastrointestinal and pulmonary [4,5,6]. Anthrax Vaccine called inhalational anthrax, is the most severe of the three forms with mortality rates for untreated human cases approaching 100%, compared with 10-20% for the cutaneous form. The release of toxins leads to anthrax, which manifests as sepsis, septic shock or meningitis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
